• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Schrodinger Inc.

    7/31/24 4:21:51 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SDGR alert in real time by email
    S-8 1 sdgr-sx8july2024.htm S-8 Document

    As filed with the Securities and Exchange Commission on July 31, 2024
    Registration No. 333-
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM S-8
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933

    Schrodinger, Inc.
    (Exact Name of Registrant as Specified in Its Charter)


    Delaware
    (State or Other Jurisdiction of
    Incorporation or Organization)
    1540 Broadway, 24th Floor
    New York, New York
    (Address of Principal Executive Offices)



    95-4284541
    (I.R.S. Employer
    Identification No.)
    10036
    (Zip Code)
    2022 Equity Incentive Plan, as amended
    2020 Employee Stock Purchase Plan, as amended
    (Full Title of the Plan)
    Ramy Farid, Ph.D.
    President and Chief Executive Officer
    Schrödinger, Inc.
    1540 Broadway, 24th Floor
    New York, New York 10036
    (Name and Address of Agent For Service)
    (212) 295-5800
    (Telephone Number, Including Area Code, of Agent For Service)



    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer☒Accelerated filer☐
    Non-accelerated filer☐Smaller reporting company☐
    Emerging growth company☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐




    PART I
    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
    Item 1.Plan Information.
    The information required by Item 1 is omitted from this registration statement and included in documents sent or given to participants in the plans covered by this registration statement pursuant to Rule 428(b)(1) of the Securities Act of 1933, as amended (the “Securities Act”).
    Item 2.Registrant Information and Employee Plan Annual Information.
    The written statement required by Item 2 is omitted from this registration statement and included in documents sent or given to participants in the plans covered by this registration statement pursuant to Rule 428(b)(1) of the Securities Act.
    PART II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
    Item 1.Incorporation of Documents by Reference.
    The registrant is subject to the informational and reporting requirements of Sections 13(a), 14, and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and in accordance therewith files reports, proxy statements and other information with the Securities and Exchange Commission (the “Commission”). The following documents listed below (File No. 001-39206), which are on file with the Commission, are incorporated in this registration statement by reference:
    (a)The registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as filed with the Commission on February 28, 2024, including the information specifically incorporated by reference into the Annual Report on Form 10-K from the registrant’s definitive proxy statement for the 2024 Annual Meeting of Stockholders;
    (b)The registrant’s Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2024 and June 30, 2024, as filed with the Commission on May 1, 2024 and July 31, 2024, respectively;
    (c)The registrant’s Current Reports on Form 8-K as filed with the Commission on February 29, 2024, June 18, 2024; and
    (d)The description of the securities contained in the registrant’s registration statement on Form 8-A filed with the Commission on January 31, 2020, as the description therein has been updated and superseded by the description of the registrant’s capital stock contained in Exhibit 4.3 to the registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as filed with the Commission on March 4, 2021, including any amendments or reports filed for the purpose of updating such description.
    All documents subsequently filed by the registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this registration statement and to be part hereof from the date of the filing of such documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this registration statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.



    Item 2.Description of Securities.
    Not applicable.
    Item 3.Interests of Named Experts and Counsel.
    Not applicable.
    Item 4.Indemnification of Directors and Officers.
    Section 102(b)(7) of the Delaware General Corporation Law (the “DGCL”), permits a corporation to eliminate or limit the personal liability of its directors or officers to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director or officer, except where the director or officer breached his or her duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law (in the case of a director), obtained an improper personal benefit or in any action by or in the right of the corporation (in the case of an officer). No such provision may eliminate or limit the liability of a director or officer for any act or omission occurring prior to the date when such provision became effective. The registrant’s certificate of incorporation provides that, to the fullest extent permitted by the DGCL, no director or officer shall be personally liable to the registrant (in the case of directors), the registrant’s stockholders (in the case of directors and officers) for monetary damages for any breach of fiduciary duty as a director or officer.
    Section 145 of the DGCL provides that a corporation has the power to indemnify a director, officer, employee or agent of the corporation and certain other persons serving at the request of the corporation in related capacities against expenses (including attorneys’ fees), judgments, fines, and amounts paid in settlements actually and reasonably incurred by the person in connection with an action, suit, or proceeding to which he or she is or is threatened to be made a party by reason of such position, if such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnification for such expenses which the Court of Chancery or such other court shall deem proper.
    The registrant’s certificate of incorporation provides that the registrant will indemnify each person who was or is a party or threatened to be made a party to any threatened, pending or completed action, suit, or proceeding, whether civil, criminal, administrative, or investigative (other than an action by or in the right of the registrant), by reason of the fact that he or she is or was, or has agreed to become, a director or officer of the registrant, or is or was serving, or has agreed to serve, at the request of the registrant, as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust, or other enterprise (all such persons being referred to as an Indemnitee), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys’ fees), judgments, fines, and amounts paid in settlement actually and reasonably incurred in connection with such action, suit, or proceeding and any appeal therefrom if such Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, the best interests of the registrant, and, with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful.
    The registrant’s certificate of incorporation also provides that the registrant will indemnify any Indemnitee who was or is a party to an action or suit by or in the right of the registrant to procure a judgment in the registrant’s favor by reason of the fact that the Indemnitee is or was, or has agreed to become, a director or officer of the registrant, or is or was serving, or has agreed to serve, at the request of the registrant as a director, officer, partner, employee, or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust, or other enterprise, or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including



    attorneys’ fees) and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding, and any appeal therefrom, if the Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, the best interests of the registrant, except that no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the registrant, unless a court determines that, despite such adjudication but in view of all of the circumstances, he or she is entitled to indemnification of such expenses. Notwithstanding the foregoing, to the extent that any Indemnitee has been successful, on the merits or otherwise, he or she will be indemnified by the registrant against all expenses (including attorneys’ fees) actually and reasonably incurred by him or her or on his or her behalf in connection therewith. If the registrant does not assume the defense, expenses must be advanced to an Indemnitee under certain circumstances.
    In addition, the registrant has entered into indemnification agreements with all of the registrant’s executive officers and directors. In general, these agreements provide that the registrant will indemnify the executive officer or director to the fullest extent permitted by law for claims arising in his or her capacity as an executive officer or director of the registrant or in connection with his or her service at the request of the registrant for another corporation or entity. The indemnification agreements also provide for procedures that will apply in the event that an executive officer or director makes a claim for indemnification and establish certain presumptions that are favorable to the executive officer or director.
    The registrant maintains a general liability insurance policy that covers certain liabilities of the registrant’s directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers.
    Item 5.Exemption from Registration Claimed.
    Not applicable.
    Item 6.Exhibits.
    The following exhibits are incorporated herein by reference:
    NumberDescription
    4.1
    Restated Certificate of Incorporation of the Registrant, as amended (incorporated by reference to Exhibit 3.1 to Registrant’s Quarterly Report on Form 10-Q (File No. 001-39206) filed with the Securities and Exchange Commission on July 31, 2024).
    4.2
    Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.1 to Registrant’s Current Report on Form 8-K (File No. 001-39206) filed with the Securities and Exchange Commission on April 13, 2023).
    5.1*
    Opinion of Wilmer Cutler Pickering Hale and Dorr LLP, counsel to the Registrant.
    23.1*
    Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1).
    23.2*
    Consent of KPMG LLP, independent registered public accounting firm.
    24.1*
    Power of attorney (included on the signature page of this registration statement).
    99.1
    2022 Equity Incentive Plan, as amended (incorporated by reference to Exhibit 10.3 to Registrant’s Quarterly Report on Form 10-Q (File No. 001-39206) filed with the Securities and Exchange Commission on July 31, 2024).
    99.2
    2020 Employee Stock Purchase Plan, as amended (incorporated by reference to Exhibit 10.4 to Registrant’s Quarterly Report on Form 10-Q (File No. 001-39206) filed with the Securities and Exchange Commission on July 31, 2024).
    107*
    Filing Fee Table.
    *Filed herewith





    Item 7.Undertakings.
    1.Item 512(a) of Regulation S-K. The undersigned registrant hereby undertakes:
    (1)To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:
    (i)To include any prospectus required by Section 10(a)(3) of the Securities Act;
    (ii)To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and
    (iii)To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;
    provided, however, that paragraphs (1)(i) and (ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the registration statement.
    (2)That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
    (3)To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
    2.Item 512(b) of Regulation S-K. The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
    3.Item 512(h) of Regulation S-K. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling



    precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.




    SIGNATURES
    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York on this 31st day of July, 2024.
    SCHRÖDINGER, INC.
    By: /s/Ramy Farid    
    Ramy Farid, Ph.D.
    President and Chief Executive Officer

    POWER OF ATTORNEY AND SIGNATURES
    We, the undersigned officers and directors of Schrödinger, Inc., hereby severally constitute and appoint Ramy Farid, Geoffrey Porges and Yvonne Tran, and each of them singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names in the capacities indicated below, the registration statement on Form S-8 filed herewith and any and all subsequent amendments to said registration statement, and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable Schrödinger, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments thereto.
    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

    SignatureTitleDate
    /s/ Ramy FaridPresident and Chief Executive Officer, Director
    Ramy Farid, Ph.D.(Principal Executive Officer)
    July 31, 2024
    /s/ Geoffrey PorgesExecutive Vice President and Chief Financial Officer
    Geoffrey Porges, MBBS(Principal Financial Officer)
    July 31, 2024
    /s/ Jenny HermanSenior Vice President, Finance and Corporate Controller
    Jenny Herman(Principal Accounting Officer)
    July 31, 2024
    /s/ Michael LyntonChairman of the Board
    July 31, 2024
    Michael Lynton
    /s/ Jeffrey ChodakewitzDirector
    July 31, 2024
    Jeffrey Chodakewitz, M.D.
    /s/ Richard FriesnerDirector
    July 31, 2024
    Richard Friesner, Ph.D.



    /s/ Gary GinsbergDirector
    July 31, 2024
    Gary Ginsberg
    /s/ Rosana Kapeller-LibermannDirector
    July 31, 2024
    Rosana Kapeller-Libermann, M.D., Ph.D.
    /s/ Arun OberoiDirector
    July 31, 2024
    Arun Oberoi
    /s/ Gary SenderDirector
    July 31, 2024
    Gary Sender
    /s/ Nancy ThornberryDirector
    July 31, 2024
    Nancy Thornberry



    Get the next $SDGR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SDGR

    DatePrice TargetRatingAnalyst
    12/15/2025$24.00Neutral → Buy
    BofA Securities
    9/30/2025$19.00Neutral
    Goldman
    8/15/2025$20.00Buy → Neutral
    Citigroup
    8/14/2025$25.00Overweight
    Barclays
    7/3/2025$28.00Equal-Weight
    Morgan Stanley
    7/2/2024$29.00Outperform
    Leerink Partners
    12/5/2023$38.00Overweight
    KeyBanc Capital Markets
    5/5/2023$60.00Overweight
    Piper Sandler
    More analyst ratings

    $SDGR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AI-Native Data Core Triggers Multi-Trillion Dollar Healthcare Structural Shift

    Issued on behalf of VentriPoint Diagnostics Ltd. VANCOUVER, BC, Jan. 29, 2026 /PRNewswire/ -- Equity-Insider.com News Commentary – The global AI medical imaging market exploded to a staggering $2.57 trillion in 2026 as the entire healthcare ecosystem ditched trial-and-error medicine for AI-native diagnostic precision and autonomous operations[1]. This massive movement has pushed the AI drug discovery sector to $1.81 billion, powered by "federated learning" models that use high-frequency sensing to collapse development timelines from years into months[2]. This new Diagnostic Data Core is creating massive tailwinds for VentriPoint Diagnostics (TSXV:VPT) (OTCPK: VPTDF), Recursion Pharmaceutical

    1/29/26 9:25:00 AM ET
    $LLY
    $RXRX
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Computer Software: Programming Data Processing

    Schrödinger Provides Update on Progress Across the Business and Outlines 2026 Strategic Priorities

    Schrödinger, Inc. (NASDAQ:SDGR) provided an update on its progress across the business in 2025 and announced its strategic priorities for 2026. The company is continuing to focus on advancing its physics+AI computational platform and serving as a global leader in computational molecular discovery. "In 2025, we witnessed the continued impact of scaling ‘physics+AI' to solve the challenges of data scarcity and to accelerate the discovery of differentiated molecules. We are entering 2026 with a clear mandate: to further strengthen our position as the essential design engine for the industry," stated Ramy Farid, Ph.D., chief executive officer at Schrödinger. "Our priorities for 2026 are focus

    1/12/26 8:30:00 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Schrödinger Partners with Lilly to Make TuneLab Platform Available in LiveDesign

    Schrödinger, Inc. (NASDAQ:SDGR) today announced a collaboration with Lilly TuneLab™, a platform launched by Eli Lilly and Company (Lilly) designed to accelerate drug discovery and development by providing access to advanced artificial intelligence (AI) capabilities. TuneLab will be made available in LiveDesign, Schrödinger's widely used enterprise informatics platform, as a priority interface for participating biotech companies to access TuneLab workflows. "As a leader in computational drug discovery, Schrödinger is pleased to partner with Lilly TuneLab," stated Pat Lorton, chief technology officer and chief operating officer, software at Schrödinger. "We are pleased that LiveDesign will

    1/9/26 7:00:00 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SDGR
    SEC Filings

    View All

    SEC Form 10-Q filed by Schrodinger Inc.

    10-Q - Schrodinger, Inc. (0001490978) (Filer)

    11/5/25 4:13:35 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Schrodinger Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Schrodinger, Inc. (0001490978) (Filer)

    11/5/25 4:09:37 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Schrodinger Inc.

    SCHEDULE 13G/A - Schrodinger, Inc. (0001490978) (Subject)

    10/27/25 6:57:10 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SDGR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Schrodinger upgraded by BofA Securities with a new price target

    BofA Securities upgraded Schrodinger from Neutral to Buy and set a new price target of $24.00

    12/15/25 9:09:21 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on Schrodinger with a new price target

    Goldman initiated coverage of Schrodinger with a rating of Neutral and set a new price target of $19.00

    9/30/25 8:57:53 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Schrodinger downgraded by Citigroup with a new price target

    Citigroup downgraded Schrodinger from Buy to Neutral and set a new price target of $20.00

    8/15/25 8:18:12 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SDGR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Dugan Margaret sold $29,387 worth of shares (1,395 units at $21.07), decreasing direct ownership by 5% to 24,574 units (SEC Form 4)

    4 - Schrodinger, Inc. (0001490978) (Issuer)

    10/17/25 4:28:13 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Chodakewitz Jeffrey was granted 5,997 shares, increasing direct ownership by 53% to 17,247 units (SEC Form 4)

    4 - Schrodinger, Inc. (0001490978) (Issuer)

    6/20/25 4:37:45 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Sender Gary was granted 5,997 shares, increasing direct ownership by 53% to 17,247 units (SEC Form 4)

    4 - Schrodinger, Inc. (0001490978) (Issuer)

    6/20/25 4:36:31 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SDGR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Schrodinger Inc.

    SC 13G - Schrodinger, Inc. (0001490978) (Subject)

    11/13/24 4:30:25 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Schrodinger Inc. (Amendment)

    SC 13G/A - Schrodinger, Inc. (0001490978) (Subject)

    2/13/24 5:13:59 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Schrodinger Inc. (Amendment)

    SC 13G/A - Schrodinger, Inc. (0001490978) (Subject)

    1/23/24 11:52:31 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SDGR
    Financials

    Live finance-specific insights

    View All

    Schrödinger Reports Third Quarter 2025 Financial Results

    Third Quarter Total Revenue of $54.3 Million, Software Revenue of $40.9 Million Updates 2025 Financial Guidance Schrödinger, Inc. (NASDAQ:SDGR) today announced financial results for the quarter ended September 30, 2025. "Schrödinger delivered a solid third quarter with software revenue growth of 28%, reflecting the industry's increasing demand for our leading computational platform," said Ramy Farid, Ph.D., chief executive officer of Schrödinger. "While we are encouraged by the continued high level of customer engagement as the macroeconomic pressures that have affected the industry stabilize, we have lowered our software revenue growth guidance by two percent to 8% to 13%. This updated

    11/5/25 4:05:00 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Schrödinger to Announce Third Quarter 2025 Financial Results on November 5

    Schrödinger (NASDAQ:SDGR) will report its third quarter 2025 financial results on Wednesday, November 5, 2025, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed in the "Investors" section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger's software platform is built on more than 30 years of R&D investment and is licensed by biotechnology, pharm

    10/22/25 8:30:00 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Schrödinger Reports Second Quarter 2025 Financial Results

    Second Quarter Total Revenue of $54.8 Million, Software Revenue of $40.5 Million Maintains Full Year 2025 Revenue Growth Guidance and Lowers Operating Expense Guidance Company to Complete Phase 1 Data Package for SGR-1505 While Exploring Strategic Opportunities for Clinical Development Initial Clinical Data for SGR-3515 and SGR-2921 Expected in Fourth Quarter of 2025 Schrödinger, Inc. (NASDAQ:SDGR) today announced financial results for the quarter ended June 30, 2025. "In a highly dynamic macroenvironment, our ability to deliver solid second quarter results and maintain our 2025 revenue growth guidance is a testament to our strong customer relationships and the demand for proven c

    8/6/25 4:05:00 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SDGR
    Leadership Updates

    Live Leadership Updates

    View All

    Schrödinger Expands Executive Leadership Team with Appointment of Mannix Aklian as Chief Commercial Officer, Global Head of Software Sales and Marketing

    Schrödinger, Inc. (NASDAQ:SDGR) today announced the expansion of its leadership team with the appointment of Mannix Aklian as executive vice president, chief commercial officer, global head of software sales and marketing. Mr. Aklian brings more than 25 years of experience in software sales and leadership roles within the biopharmaceutical and technology industries. Mr. Aklian will have global oversight of Schrödinger's account management teams and will be responsible for the continued growth of the company's software business, including the go-to-market strategy for enhancements and new products within Schrödinger's computational platform. "Mannix joins Schrödinger at a pivotal time as w

    5/29/25 8:00:00 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Schrödinger Expands Board of Directors with Appointment of Bridget van Kralingen

    Schrödinger, Inc. (NASDAQ:SDGR) today announced the appointment of Bridget van Kralingen to its Board of Directors, effective March 7, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250310010062/en/Bridget van Kralingen was appointed to Schrödinger's Board of Directors in March 2025. (Photo: Business Wire) "Bridget has a proven track record of growing global software businesses, and we are pleased to welcome her to our Board," said Ramy Farid, Ph.D., chief executive officer of Schrödinger. "Bridget's leadership experience overseeing strategic initiatives at global technology companies, including IBM, will be valuable to Sch

    3/10/25 8:30:00 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Schrödinger Appoints Geoffrey Porges as Chief Financial Officer

    Schrödinger, Inc. (NASDAQ:SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced the appointment of Geoffrey Porges, MBBS., as chief financial officer. Dr. Porges brings to Schrödinger more than 30 years of experience in executive, advisory and investment roles within the biopharmaceutical industry. As Schrödinger's CFO, he will lead all aspects of the company's financial operations and investor relations and corporate affairs activities. He will also oversee business development and strategic planning for the company's proprietary pharmaceuticals and biopharmaceutical collaborations. This press release features multim

    8/18/22 7:01:00 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care